Liver function and drug levels: a repotrectinib study
NCT ID NCT06352528
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a single dose of the drug repotrectinib stays in the blood of people with moderate or severe liver impairment compared to healthy volunteers. 18 adults took part to help understand if liver problems change drug levels. The results will guide dosing for patients with liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Orlando Clinical Research Center
Orlando, Florida, 32809-3017, United States
-
Panax Clinical Research
Miami Lakes, Florida, 33014-2811, United States
-
The Texas Liver Institute, Inc.
San Antonio, Texas, 78215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Liver health and drug processing: a closer look at casdatifan